Log in

Horizon Therapeutics Stock Forecast, Price & News

+2.92 (+3.88 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $78.25
50-Day Range
MA: $73.87
52-Week Range
Now: $78.25
Volume1.50 million shs
Average Volume2.23 million shs
Market Capitalization$16.16 billion
P/E Ratio32.07
Dividend YieldN/A
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More
Horizon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.85 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HZNP



Sales & Book Value

Annual Sales$1.30 billion
Cash Flow$3.55 per share
Book Value$11.67 per share


Net Income$573.02 million


Market Cap$16.16 billion
Next Earnings Date11/4/2020 (Estimated)
+2.92 (+3.88 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions

How has Horizon Therapeutics' stock price been impacted by COVID-19?

Horizon Therapeutics' stock was trading at $30.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HZNP stock has increased by 156.5% and is now trading at $78.25.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Horizon Therapeutics

When is Horizon Therapeutics' next earnings date?

Horizon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Horizon Therapeutics

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics PLC (NASDAQ:HZNP) released its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. The biopharmaceutical company earned $462.80 million during the quarter, compared to the consensus estimate of $333.70 million. Horizon Therapeutics had a net margin of 34.09% and a return on equity of 19.67%. The firm's quarterly revenue was up 44.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.49 EPS.
View Horizon Therapeutics' earnings history

What guidance has Horizon Therapeutics issued on next quarter's earnings?

Horizon Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85-1.9 billion, compared to the consensus revenue estimate of $1.54 billion.

What price target have analysts set for HZNP?

12 Wall Street analysts have issued 1-year price objectives for Horizon Therapeutics' shares. Their forecasts range from $35.00 to $112.00. On average, they anticipate Horizon Therapeutics' share price to reach $77.31 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Horizon Therapeutics

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Alibaba Group (BABA), Opko Health (OPK), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and TherapeuticsMD (TXMD).

Who are Horizon Therapeutics' key executives?

Horizon Therapeutics' management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
  • Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
  • Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics' major shareholders?

Horizon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.60%), William Blair Investment Management LLC (3.69%), FMR LLC (3.53%), Paulson & CO. Inc. (3.34%), Orbimed Advisors LLC (1.39%) and Nuveen Asset Management LLC (1.27%). Company insiders that own Horizon Therapeutics stock include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani.
View institutional ownership trends for Horizon Therapeutics

Which major investors are selling Horizon Therapeutics stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Paulson & CO. Inc., Jennison Associates LLC, Glenmede Trust Co. NA, William Blair Investment Management LLC, Viking Global Investors LP, Bank of Montreal Can, and First Trust Advisors LP. Company insiders that have sold Horizon Therapeutics company stock in the last year include Barry Moze, Brian K Beeler, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani.
View insider buying and selling activity for Horizon Therapeutics

Which major investors are buying Horizon Therapeutics stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, FMR LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Summit Partners Public Asset Management LLC, Scout Investments Inc., Orbimed Advisors LLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Horizon Therapeutics

How do I buy shares of Horizon Therapeutics?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HZNP stock can currently be purchased for approximately $78.25.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $16.16 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics employs 1,200 workers across the globe.

What is Horizon Therapeutics' official website?

The official website for Horizon Therapeutics is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected].

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.